Outlook Therapeutics Insider Bets $5 Million as FDA Clears Path for Eye Drug
A director at Outlook Therapeutics has put more than $5 million of his own money on the line, scooping up...
A director at Outlook Therapeutics has put more than $5 million of his own money on the line, scooping up...
A miscalculation in maintenance scheduling can prove far more costly than the price of a skipped inspection. German employers who...
When a wind turbine caught fire near Bönen in North Rhine-Westphalia last week, the blaze forced a complete shutdown of...
Qualcomm is sprinting toward June 24 with two very different growth narratives pulling the stock in opposite directions. The chipmaker...
The final week of June is shaping up as a make-or-break moment for Green Bridge Metals, with a triple set...
Palantir secured two significant commercial agreements in as many weeks, yet its shares ended the week at €110.66 — a...
Deutz is rewriting its identity. The Cologne-based engine builder, long synonymous with powering tractors and construction equipment, is now making...
The contrast between ambition and reality at Xiaomi has rarely been starker. A 43 percent collapse in adjusted net profit...
The story of D-Wave Quantum right now is a tale of two very different kinds of validation. One comes from...
The gap between Munich Re’s operational achievements and its stock market performance has rarely been wider. Less than a week...
StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.
© 2023 StocksToday.com